Arakoda Approved to Prevent Malaria
August 8, 2018 – The U.S. FDA has approved Arakoda™ (tafenoquine), developed by 60 Degrees Pharmaceuticals in partnership with the United States Army, to prevent malaria in adults. This is the second FDA approval of a tafenoquine product in four weeks. Krintafel (tafenoquine), which was developed by GlaxoSmithKline and Medicines for Malaria Venture (MMV), received FDA approval on July 20, 2018. It is approved to prevent relapse in patients who have already been infected with Plasmodium vivax, one of several organisms responsible for malaria in humans.
In contrast, Arakoda is meant for use by individuals who have not been infected with malaria. Patients should take Arakoda at a loading dose of 200mg per day for three days before traveling to a region where malaria is present. They should then switch to a maintenance regimen of 200mg once a week while in the region, beginning seven days after they have completed the loading dose. Once patients have left the area where malaria is present, they should take one more 200mg dose of Arakoda seven days after their last maintenance dose.
As with Krintafel, patients should be tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency prior to beginning treatment, due to potential for hemolytic anemia. The drug should not be used by women who are pregnant, or who are nursing infants who have G6PD deficiency.
Arakoda is anticipated to launch in 2019. Pricing plans are not yet available.